|
Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm focused on cancer immunotherapy - Receives formal notification of the grant for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application from the IP Australia patent office. Says the patent covers the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, supported by Poolbeg’s proprietary data. ‘This represents the first national grant within Poolbeg’s cancer immunotherapy-induced CRS patent family, marking an important milestone for the company,’ Poolbeg says. Adds that the grant further strengthens its ‘robust intellectual property portfolio, enhancing POLB 001’s future value and appeal to potential partners.’ Chief Executive Officer Jeremy Skillington comments: ‘The grant...represents an important step in strengthening our global intellectual property position for POLB 001. With the TOPICAL trial on track to deliver interim data in summer 2026, the timing of this first patent grant could not be better. Protection in this indication is a key component of our strategy, and securing this coverage in Australia provides valuable support for the continued advancement of POLB 001. We look forward to progressing corresponding applications in other jurisdictions, expedited by the use of the patent prosecution highway international framework.’ Current stock price: 4.52 pence, up 8.9% on Tuesday in London 12-month change: up 64% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
